We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Grant Awarded to Advance Biopharmaceutical Scale-up of Vaccine

Grant Awarded to Advance Biopharmaceutical Scale-up of Vaccine

Grant Awarded to Advance Biopharmaceutical Scale-up of Vaccine

Grant Awarded to Advance Biopharmaceutical Scale-up of Vaccine

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Grant Awarded to Advance Biopharmaceutical Scale-up of Vaccine"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PnuVax Incorporated, an organization dedicated to the production of high quality vaccines and biopharmaceuticals for the promotion of public health worldwide, today announced that it is the recipient of a $29.4 million USD ($36 million CDN) grant. The grant will be used to further develop and clinically evaluate PnuVax’s innovative pneumococcal conjugate vaccine. Milestone payments will be received over the next three years as the vaccine progresses from process development through to biomanufacturing scale-up and proof-of-concept clinical trials.

Despite the current commercial availability of pneumococcal conjugate vaccines, pneumonia remains the single leading cause of death for children under 5 years of age worldwide. “Children are still dying of preventable diseases such as pneumonia worldwide, largely due to high dosage costs and supply shortages that can thwart delivery to developing countries,” said PnuVax Co-Founder Jonas Elliott Gerson.

PnuVax’s vaccine provides coverage against multiple serotypes, or distinct variations, of the pneumoniacausing pneumococcus bacterium. Use of PnuVax’s unique patented conjugation platform technology to produce the vaccine is expected to speed up biomanufacturing and increase yield for a greatly reduced perdose cost. PnuVax plans to manufacture its vaccine in Montreal, Canada using innovative methods to create a low-cost product to be distributed to the developing world via Gavi, the Vaccine Alliance and Unicef, to the world’s poorest communities, significantly increasing access.

“Creating a healthy marketplace for vaccines is crucial to our efforts to protect every child through immunization,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance, “That’s why this grant to a potential new and innovative supplier is so important. Gavi has now helped 58 countries to introduce pneumococcal vaccine since our support started in 2009 and coverage is steadily increasing. This vaccine is at the forefront of our fight against pneumonia."

Donald F. Gerson, PnuVax CEO, said: “PnuVax is delighted to partner with the Bill & Melinda Gates Foundation to develop and evaluate this needed vaccine during our upcoming early stage clinical trials. Once licensed, this vaccine is expected to increase supply of low-cost pneumococcal conjugate vaccine on a global scale.”

In addition to aiding the international community, PnuVax also intends to provide this vaccine to Canadians at a reduced cost, especially those in communities most in need. PnuVax Co-Founder Allison Turner said: “Pneumonia remains a significant problem in many of Canada’s Northern communities1 and one of PnuVax’s specific objectives, in addition to serving the developing world, is to help reduce the incidence of childhood pneumonia in Canada.2

PnuVax’s platform technology can be used in the manufacture of vaccines for a broad range of infectious diseases. Prior to the current funding, PnuVax received two grants from the Bill & Melinda Gates Foundation for the pre-clinical development of their vaccine.3

This article has been republished from materials provided by PnuVax Incorporated. Note: material may have been edited for length and content. For further information, please contact the cited source.


1. Respiratory disease in Canadian First Nations and Inuit children, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3448538/. 
2. PnuVax’s large-scale biomanufacturing facility in Canada is fully equipped to produce large quantities of GMP material for both vaccines and therapeutic proteins. This is in line with Government of Canada’s partnership with the Gates Foundation to move global health forward and the Gates Foundation and UN’s $2.3 billion USD Muskoka Initiative.
3. PnuVax received funding in 2014 from the Gates Foundation to develop a pneumococcal conjugate vaccine, to be manufactured at a significantly reduced cost. This funding was increased in 2015 to allow for continued product testing of PnuVax’s vaccine.